TECX
Tectonic Therapeutic, Inc.
$29.10
+0.34%
$549.1M
No data for this timeframe.
Vol
Market Cap$549.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders6 funds
Inst. Value$76.4M
Inst. Activity1 buys / 1 sells
Insider Activity3B / 5S
Insider Net $-$345.6K
SEC Reports6
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. NY·CIK 0001681087·Prev Close $29.00
Recent Activity
May 7, 2026
SEC
Tectonic Therapeutic reported Q1 2026 net loss of $25.2M (-$1.34/share), missing consensus of -$1.16 by 15.5%. R&D spend
8-K — Impact 5/10
May 7, 2026
SEC
Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a year ago, driven by inc
PRESS-RELEASE — Impact 4/10
May 7, 2026
earnings
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
<p>WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Track
May 4, 2026
Insider
Ruddy Marcella K. sold 1,065 shares
Chief Medical Officer @ $30.00 ($31.9K)
Apr 24, 2026
SEC
Tectonic Therapeutic, Inc. (TECX) is holding its 2026 Annual Meeting to vote on the election of two directors (Timothy A
DEFA14A — Impact 3/10
Apr 1, 2026
Insider
Ruddy Marcella K. sold 1,000 shares
Chief Medical Officer @ $31.05 ($31.1K)
Apr 1, 2026
Insider
Nader Francois sold 20,400 shares
Director @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — ADD
9,225 shares ($192.4K)
Price Targets
$78.44
+174.7% upside
Strong Buy
Current $28.56
Low $60.00
Median $80.00
High $101.00
9 analysts
$60.00
$101.00
Analyst Ratings
6Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Raymond James | UPGRADE | Outperform → Strong Buy |
| Apr 14, 2026 | Stifel | INITIATE | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.35 ▼ -12.9% | $-1.47 — $-1.25 | -27% YoY | 8 |
| Next Q | $-1.37 ▼ -9.7% | $-1.53 — $-1.23 | -34% YoY | 8 |
| Current FY | $-5.32 ▼ -9.0% | $-5.68 — $-4.79 | -31% YoY | 9 |
| Next FY | $-5.68 ▼ -5.1% | $-6.33 — $-3.26 | -7% YoY | 9 |
Latest Reports
BEARISH
8-K
5/10
Tectonic Therapeutic reported Q1 2026 net loss of $25.2M (-$1.34/share), missing consensus of -$1.16 by 15.5%. R&D spend
May 7, 2026
NEUTRAL
PRESS-RELEASE
4/10
Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a year ago, driven by inc
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $58.6M | ADD |
| VANGUARD GROUP INC | $12.5M | ADD |
| WELLS FARGO & COMPANY/MN | $2.5M | ADD |
| MORGAN STANLEY | $2.0M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $677.1K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 4, 2026 | Ruddy Marcella | SELL | $31.9K |
| Apr 1, 2026 | Ruddy Marcella | SELL | $31.1K |
| Apr 1, 2026 | Nader Francois | A | $0.00 |
| Mar 6, 2026 | Ruddy Marcella | SELL | $300.0K |
| Mar 6, 2026 | McNamara Peter | M | $6.0K |
6 institutional holders with $76.4M total value (3,663,872 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 2,807,442 | $58.6M | 76.6% | ADD +84.6% |
| 2 | VANGUARD GROUP INC | 599,898 | $12.5M | 16.4% | ADD +61.8% |
| 3 | WELLS FARGO & COMPANY/MN | 120,411 | $2.5M | 3.3% | ADD +40.8% |
| 4 | MORGAN STANLEY | 94,435 | $2.0M | 2.6% | TRIM -34.7% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 32,461 | $677.1K | 0.9% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 9,225 | $192.4K | 0.3% | ADD +44.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 6,365 | 9,225 | +44.9% | $192.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 93,400 | 0 | -100.0% | $0.00 | 2025-Q4 |
| MORGAN STANLEY | TRIM | 160,430 | 104,733 | -34.7% | $1.6M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 72,772 | 102,473 | +40.8% | $1.6M | 2025-Q3 |
| UBS Group AG | ADD | 34,238 | 66,460 | +94.1% | $1.0M | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 361,168 | 584,393 | +61.8% | $11.6M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 144,302 | 86,987 | -39.7% | $1.7M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 32,771 | 72,772 | +122.1% | $1.4M | 2025-Q2 |
| UBS Group AG | DOUBLED | 11,227 | 34,238 | +205.0% | $680.3K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 32,365 | — | $643.1K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 65,701 | 6,922 | -89.5% | $137.5K | 2025-Q2 |
| FMR LLC | ADD | 1,516,335 | 2,799,400 | +84.6% | $49.6M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 17,415 | 164,235 | +843.1% | $2.9M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 48,173 | 144,302 | +199.5% | $2.6M | 2025-Q1 |
| CITADEL ADVISORS LLC | NEW | — | 93,474 | — | $1.6M | 2025-Q1 |
| WELLS FARGO & COMPANY/MN | ADD | 18,513 | 32,771 | +77.0% | $580.4K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 4,711 | 0 | -100.0% | $0.00 | 2025-Q1 |
| MORGAN STANLEY | ADD | 13,321 | 17,415 | +30.7% | $804.0K | 2024-Q4 |
| UBS Group AG | DOUBLED | 3 | 10,774 | +359033.3% | $497.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 4,711 | — | $217.5K | 2024-Q4 |
6 unique insiders with 8 transactions. Net insider value: -$345.6K ($235.2K bought, $580.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 4, 2026 | Ruddy Marcella K. | Chief Medical Officer | SELL | 1,065 | $30.00 | $31.9K |
| Apr 1, 2026 | Ruddy Marcella K. | Chief Medical Officer | SELL | 1,000 | $31.05 | $31.1K |
| Apr 1, 2026 | Nader Francois | Director | A | 20,400 | $0.00 | $0.00 |
| Mar 6, 2026 | Ruddy Marcella K. | Chief Medical Officer | SELL | 10,000 | $30.00 | $300.0K |
| Mar 6, 2026 | McNamara Peter | Chief Scientific Officer | M | 2,500 | $2.38 | $6.0K |
| Mar 6, 2026 | McNamara Peter | Chief Scientific Officer | M | 2,500 | $0.00 | $0.00 |
| Mar 6, 2026 | McNamara Peter | Chief Scientific Officer | SELL | 6,047 | $30.00 | $181.4K |
| Mar 4, 2026 | Ruddy Marcella K. | Chief Medical Officer | A | 24,250 | $0.00 | $0.00 |
| Mar 4, 2026 | Schwabish Marc | Chief Business Officer | A | 17,750 | $0.00 | $0.00 |
| Mar 4, 2026 | Ruddy Marcella K. | Chief Medical Officer | A | 26,500 | $0.00 | $0.00 |
| Mar 4, 2026 | McNamara Peter | Chief Scientific Officer | A | 23,000 | $0.00 | $0.00 |
| Mar 4, 2026 | McNamara Peter | Chief Scientific Officer | A | 21,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Schwabish Marc | Chief Business Officer | A | 19,500 | $0.00 | $0.00 |
| Mar 4, 2026 | REICIN ALISE | Chief Executive Officer | A | 76,500 | $0.00 | $0.00 |
| Mar 4, 2026 | REICIN ALISE | Chief Executive Officer | A | 69,250 | $0.00 | $0.00 |
| Mar 3, 2026 | McNamara Peter | Chief Scientific Officer | SELL | 1,649 | $22.06 | $36.4K |
| Feb 11, 2026 | REICIN ALISE | Chief Executive Officer | BUY | 2,500 | $21.10 | $52.8K |
| Feb 11, 2026 | REICIN ALISE | Chief Executive Officer | BUY | 2,500 | $21.10 | $52.8K |
| Feb 10, 2026 | Lochner Daniel | Chief Financial Officer | BUY | 6,000 | $21.61 | $129.7K |
| Feb 10, 2026 | Schwabish Marc | Chief Business Officer | M | 4,500 | $0.00 | $0.00 |
| Feb 10, 2026 | Schwabish Marc | Chief Business Officer | M | 4,500 | $2.38 | $10.7K |
| Feb 4, 2026 | Lochner Daniel | Chief Financial Officer | F | 2,077 | $23.22 | $48.2K |
| Feb 4, 2026 | REICIN ALISE | Chief Executive Officer | F | 4,104 | $23.22 | $95.3K |
| Feb 4, 2026 | Schwabish Marc | Chief Business Officer | F | 1,619 | $23.22 | $37.6K |
| Feb 4, 2026 | McNamara Peter | Chief Scientific Officer | F | 1,748 | $23.22 | $40.6K |
| Feb 4, 2026 | Ruddy Marcella K. | Chief Medical Officer | F | 2,064 | $23.22 | $47.9K |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 5 neutral. Avg impact: 3.5/10.
BEARISH
8-K
5/10
Tectonic Therapeutic reported Q1 2026 net loss of $25.2M (-$1.34/share), missing consensus of -$1.16
May 7, 2026
NEUTRAL
PRESS-RELEASE
4/10
Tectonic Therapeutic reported Q1 2026 EPS of -$1.34, a 44% wider net loss of $25.2M vs -$15.9M a yea
May 7, 2026
NEUTRAL
DEFA14A
3/10
Tectonic Therapeutic, Inc. (TECX) is holding its 2026 Annual Meeting to vote on the election of two
Apr 24, 2026
NEUTRAL
3
2/10
Francois Nader, a reporting owner at Tectonic Therapeutic, Inc., filed a Form 3 indicating no benefi
Apr 3, 2026
NEUTRAL
CLUSTER
4/10
Tectonic Therapeutic insiders executed a mix of open-market sales and non-cash derivative/award tran
Mar 9, 2026
NEUTRAL
8-K
3/10
Tectonic Therapeutic appointed François Nader as Chair and independent director of the Board, replac
Feb 24, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 6 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$78.44 mean target
+174.7% upside
Strong Buy (1.10)
$60.00 Low
$101.00 High
| Metric | Value |
|---|---|
| Current Price | $28.56 |
| Target Low | $60.00 |
| Target Mean | $78.44 |
| Target Median | $80.00 |
| Target High | $101.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.10) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.35 | $-1.47 | $-1.25 | -26.6% | -12.9% | 0↑ 7↓ | $0.0B | 0.0% | 8 |
| Next Q 2026-09-30 |
$-1.37 | $-1.53 | $-1.23 | -34.2% | -9.7% | 1↑ 7↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-5.32 | $-5.68 | $-4.79 | -31.4% | -9.0% | 2↑ 7↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-5.68 | $-6.33 | $-3.26 | -6.7% | -5.1% | 2↑ 7↓ | $0.0B | 0.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.355 | |
| 7d ago | $-1.355 | |
| 30d ago | $-1.200 | -0.155 |
| 60d ago | $-1.187 | -0.168 |
| 90d ago | $-1.202 | -0.153 |
3 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Raymond James | UPGRADE | Outperform | Strong Buy |
| Apr 14, 2026 | Stifel | INITIATE | — | Buy |
| Jan 8, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 5 | 10 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 10 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 7, 2026
earnings
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
<p>WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kd0PWL20AOO7SuUM63TJLLG9yebm1IofoLFv8uDAPm
May 7, 2026
earnings_calendar
TECX Q1 2026 Earnings Scheduled — 2026-05-07
Apr 23, 2026
other
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
<p>WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=n7LKpo2UyblQRcviyW5xfobgjvXkK2xt14RvVLVH
Mar 16, 2026
short_interest
FTD: TECX — 16,028 shares ($0.5M) failed to deliver
Settlement: 20260316, Price: $33.31, FTD Value: $533,892.68, TECTONIC THERAPEUTIC INC COM (
Mar 12, 2026
short_interest
FTD: TECX — 22,290 shares ($0.8M) failed to deliver
Settlement: 20260312, Price: $34.79, FTD Value: $775,469.1, TECTONIC THERAPEUTIC INC COM (
Mar 11, 2026
short_interest
FTD: TECX — 49,402 shares ($1.6M) failed to deliver
Settlement: 20260311, Price: $33.24, FTD Value: $1,642,122.48, TECTONIC THERAPEUTIC INC COM (
Mar 10, 2026
short_interest
FTD: TECX — 153,025 shares ($5.2M) failed to deliver
Settlement: 20260310, Price: $34.00, FTD Value: $5,202,850, TECTONIC THERAPEUTIC INC COM (
Mar 9, 2026
short_interest
FTD: TECX — 138,755 shares ($5.0M) failed to deliver
Settlement: 20260309, Price: $35.87, FTD Value: $4,977,141.85, TECTONIC THERAPEUTIC INC COM (
Mar 6, 2026
short_interest
FTD: TECX — 50,123 shares ($1.4M) failed to deliver
Settlement: 20260306, Price: $27.85, FTD Value: $1,395,925.55, TECTONIC THERAPEUTIC INC COM (
Mar 2, 2026
other
Tectonic Therapeutic to Participate in March Investor Conferences
<p>WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=USLknVc-Rj1NyzzPkYCS4saYNxB3qWTNWram5XZz
Feb 26, 2026
short_interest
FTD: TECX — 23,164 shares ($0.5M) failed to deliver
Settlement: 20260226, Price: $23.11, FTD Value: $535,320.04, TECTONIC THERAPEUTIC INC COM (
Feb 13, 2026
short_interest
FTD: TECX — 31,931 shares ($0.7M) failed to deliver
Settlement: 20260213, Price: $22.71, FTD Value: $725,153.01, TECTONIC THERAPEUTIC INC COM (
Feb 11, 2026
short_interest
FTD: TECX — 92,741 shares ($2.0M) failed to deliver
Settlement: 20260211, Price: $21.05, FTD Value: $1,952,198.05, TECTONIC THERAPEUTIC INC COM (
Feb 6, 2026
short_interest
FTD: TECX — 101,541 shares ($2.3M) failed to deliver
Settlement: 20260206, Price: $22.86, FTD Value: $2,321,227.26, TECTONIC THERAPEUTIC INC COM (